Literature DB >> 4628901

Pseudomonas aeruginosa: immune status in patients with cystic fibrosis.

R G Doggett, G M Harrison.   

Abstract

In order to have a better understanding of the clinical significance of Pseudomonas aeruginosa, circulating and secretory antibodies were measured. Of 100 patients diagnosed as having cystic fibrosis (CF) and an atypical mucoid P. aeruginosa cultured from their sputum, each possessed serum precipitins. These immunoprecipitates, however, were not detected in the sera of 40 CF patients, some of whom were chronically ill with pulmonary colonization by typically rough-smooth strains of P. aeruginosa. The sera of 46 CF patients and 27 CF patient parents not colonized by P. aeruginosa were negative for the precipitins. The sera from 15 of 45 chronically ill patients not having CF, however, but harboring P. aeruginosa, also possessed serum precipitins. The sera from 85 subjects not having CF and not clinically infected with P. aeruginosa were negative for precipitins. Serum hemagglutination titers as high as 1:4096 were measured in older CF patients having advanced pulmonary disease and who were infected with mucoid P. aeruginosa. Salivary titers ranged from 1:8 to 1:64. Increased levels of both circulating and secretory antibodies of the immunoglobulin A and G classes were demonstrated in patients with CF. Once a patient with CF becomes colonized with P. aeruginosa a process of conversion from the rough and smooth forms to the mucoid form is almost inevitable. Although the mucoid form predominates in the sputum, intermediates of the various colony types are often present. Serum precipitins were demonstrable only after the appearance of mucoid strains in the sputum of patients with CF. Although antibiotics tend to reduce the number of mucoid microorganisms, they are rarely, if ever, eradicated from these patients' lungs. Recurrent episodes of servere pulmonary infection and the evidence of increasing antibody formation to mucoid strains indicates the invasiveness of these particular strains.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4628901      PMCID: PMC422584          DOI: 10.1128/iai.6.4.628-635.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  The IgA system. 3. IgA levels in the serum and saliva of pediatric patients--evidence for a local immunological system.

Authors:  M A South; W J Warwick; F A Wolheim; R A Good
Journal:  J Pediatr       Date:  1967-11       Impact factor: 4.406

2.  Natural antibodies of human serum, saliva, and urine reactive with Escherichia coli.

Authors:  D Tourville; J Bienenstock; T B Tomasi
Journal:  Proc Soc Exp Biol Med       Date:  1968-07

3.  Immunoglobulin production in bronchial mucosa and bronchial lymph nodes, particularly in cystic fibrosis of the pancreas.

Authors:  F J Martinez-Tello; D G Braun; W A Blanc
Journal:  J Immunol       Date:  1968-11       Impact factor: 5.422

4.  Bacterial precipitins in serum of patients with cystic fibrosis.

Authors:  M W Burns; J R May
Journal:  Lancet       Date:  1968-02-10       Impact factor: 79.321

5.  Polyuronic acids produced by Pseudomonas aeruginosa.

Authors:  D M Carlson; L W Matthews
Journal:  Biochemistry       Date:  1966-09       Impact factor: 3.162

6.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

7.  Mucoid Pseudomonas aeruginosa in patients with chronic illnesses.

Authors:  R G Doggett; G M Harrison; R E Carter
Journal:  Lancet       Date:  1971-01-30       Impact factor: 79.321

8.  Serogroups of Pseudomonas aeruginosa and the immune response of patients with cystic fibrosis.

Authors:  E Diaz; L L Mosovich; E Neter
Journal:  J Infect Dis       Date:  1970-03       Impact factor: 5.226

9.  Incidence of mucoid Pseudomonas aeruginosa from clinical sources.

Authors:  R G Doggett
Journal:  Appl Microbiol       Date:  1969-11

10.  Serum immunoglobulin levels in cystic fibrosis.

Authors:  R H Schwartz
Journal:  Am J Dis Child       Date:  1966-04
View more
  24 in total

1.  Intracellular killing of different strains of Pseudomonas aeruginosa by human leucocytes.

Authors:  E A Roe; R J Jones
Journal:  Br J Exp Pathol       Date:  1974-08

2.  Cystic fibrosis in adults: the unsuspected pulmonary diagnosis.

Authors:  A J Nolan
Journal:  Can Med Assoc J       Date:  1976-01-24       Impact factor: 8.262

3.  Demonstration of uronic acid capsular material in the cerebrospinal fluid of a patient with meningitis caused by mucoid Pseudomonas aeruginosa.

Authors:  D Stevens; M Lieberman; T McNitt; J Price
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

4.  Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.

Authors:  R J Jones; E A Roe
Journal:  Br J Exp Pathol       Date:  1975-02

Review 5.  Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients.

Authors:  T B May; D Shinabarger; R Maharaj; J Kato; L Chu; J D DeVault; S Roychoudhury; N A Zielinski; A Berry; R K Rothmel
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

6.  Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis.

Authors:  G Döring; N Høiby
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

7.  Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay.

Authors:  L E Bryan; A Kureishi; H R Rabin
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

8.  Interaction of a rat lung lectin with the exopolysaccharides of Pseudomonas aeruginosa.

Authors:  H A McArthur; H Ceri
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

9.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

10.  Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs.

Authors:  J E Pennington; W F Hickey; L L Blackwood; M A Arnaut
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.